Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic insulin sensitivity refers to the ability of liver cells (hepatocytes) to respond appropriately to the hormone insulin. In a healthy state, when blood glucose rises after eating, pancreatic beta cells release insulin. This hormone binds to its receptor on hepatocytes and triggers signaling cascades that suppress hepatic glucose production (mainly by inhibiting gluconeogenesis), promote glycogen synthesis, and regulate lipid metabolism[2][6]. When hepatic insulin sensitivity is impaired—termed *hepatic insulin resistance*—the liver fails to suppress glucose output in response to normal or elevated levels of circulating insulin. This leads to increased fasting blood sugar and contributes significantly to the development of type 2 diabetes mellitus and non-alcoholic fatty liver disease[1][3][5]. Hepatic insulin sensitivity is not a single molecule or receptor but rather describes a physiological property or functional state involving multiple molecular players such as the **insulin receptor**, IRS proteins, PI3K/Akt pathway components, mTORC1 complex, transcription factors like FoxO1 and SREBP1c, among others[2][4]. Therefore, it is not considered a canonical therapeutic target itself but rather an outcome or readout reflecting how well these pathways function collectively. In summary: > "Hepatic insulin sensitivity" is not a discrete molecular entity but describes how effectively hepatocytes respond at the molecular level to circulating insulin; it reflects integrated signaling through several well-characterized molecules including—but not limited—to the hepatic **insulin receptor**[2][6]. Because this term does **not refer specifically** to an individual protein/receptor/enzyme/transporter/transcription factor/etc., it should be marked as "is_incorrect: true" for structured drug target databases. The correct approach would be targeting specific molecules involved in hepatic insulin signaling such as "Insulin receptor," "PI3K," or "Akt."
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic insulin sensitivity.